MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2017

Mar 8, 2017

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

MAYNE PHARMA ACQUIRES RIGHTS TO GENERIC DURAGESIC[®] PATCH FOR THE US

9 March 2017, Adelaide, South Australia

• Mayne Pharma Group Limited (ASX: MYX) adds fentanyl transdermal delivery system (TDS) to its US generic product portfolio

• The deal strengthens alliance with Corium International, Inc. (Corium), a new strategic partnership established following the acquisition of a portfolio of US generic products from Teva Pharmaceutical Industries Limited (Teva Portfolio) in August 2016

Mayne Pharma is pleased to announce it has acquired the rights to the fentanyl transdermal delivery system (TDS), 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr from Par Pharmaceutical, Inc. (Par). This product was developed by Corium, a specialty pharmaceutical company focused on the development and manufacture of transdermal and transmucosal delivery systems.

Fentanyl TDS is an AB-rated generic equivalent to Duragesic®, indicated for the management of pain in opioid-tolerant patients, severe enough to require daily treatment. Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium, acquired select inventory and the rights to market the product in the US from today. According to IMS Health, the annual market sales for the fentanyl patch were approximately US$560 million for the 12 months ending 31 December 2016.

Mayne Pharma’s CEO, Mr Scott Richards, said “We are very pleased to have partnered with Corium on another complex, difficult-to-develop and manufacture product. The US transdermal patch market is valued at more than US$3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance.”

“Mayne Pharma’s first marketed patch was Clonidine, indicated for the treatment of hypertension and is one of Mayne Pharma’s top five generic products by sales. Our alliance with Corium now includes two marketed and one pipeline product that is filed with the US Food and Drug Administration and reinforces one of the key strategic benefits of the Teva Portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharamceutical ingredient suppliers and contract development and manufacturing companies.”

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

==> picture [125 x 126] intentionally omitted <==

Page 1

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

For further information, please visit www.maynepharma.com

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialisation of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble.

The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor® , a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch codeveloped with Agile Therapeutics and additional transdermal products that are being developed with other partners.

For further information, please visit www.coriumgroup.com

Duragesic® is a registered trademark of Johnson & Johnson Corporation.

==> picture [125 x 126] intentionally omitted <==

Page 2